Newsletter

Biotech Stocks

This Phase 2 ASX Biotech Has a Drug That Is One of Its Kind and Has Been Progressing Nicely!

Phase 2 ASX Biotech Prescient Therapeutics (ASX:PTX) has spent the better part of a decade building up to the point it is at now. 2026 has become the year in which the investment case is finally coming into focus. PTX‑100 is the world’s first GGTase‑1 inhibitor to enter human trials, and it remains the only…

ByNick SundichJune 25, 2026

Cynata (ASX:CYP) Phase 3 knee trial misses and Cymerus is now under review

Cynata Therapeutics (ASX:CYP) Phase 3 knee osteoarthritis trial missed both endpoints, triggering a review of the entire Cymerus platform.

ByCharlie YouldenJune 19, 2026

BCAL Diagnostics (ASX:BDX) BREASTEST Monitor flags 91% sensitivity in early recurrence read

BCAL Diagnostics (ASX:BDX) unveiled BREASTEST Monitor, a blood test for breast cancer recurrence with 91% sensitivity in early validation data.

ByCharlie YouldenJune 18, 2026

Microba (ASX:MAP) raises A$5m and Sonic Healthcare keeps writing cheques

Microba Life Sciences (ASX:MAP) raises A$5m at a 20.6% discount with Sonic Healthcare backing the round, targeting CY2027 cashflow break-even.

ByCharlie YouldenJune 12, 2026

LTR Pharma (ASX:LTP) lands 150,000-unit ROXUS deal that anchors the US story

LTR Pharma (ASX:LTP) signs a binding US telehealth term sheet with Shed Holdings, locking in a 150,000-unit ROXUS minimum volume floor.

ByCharlie YouldenJune 9, 2026

Why Our Home Grown ASX Success Stories Are Doomed To Be Given Away on the Cheap, And What Could Be Done

There are plenty of ASX Success Stories that can be categorised as such because they were bought out by a major player. Shareholders who rode things out over the journey will walk away satisfied without thought that they could be getting more. If the board (and perhaps a substantial shareholder or two) backs the bid,…

ByNick SundichJune 9, 2026

the Kick-ass Multipurpose WordPress Theme

Biotech Stocks

This Phase 2 ASX Biotech Has a Drug That Is One of Its Kind and Has Been Progressing Nicely!

Cynata (ASX:CYP) Phase 3 knee trial misses and Cymerus is now under review

BCAL Diagnostics (ASX:BDX) BREASTEST Monitor flags 91% sensitivity in early recurrence read

Microba (ASX:MAP) raises A$5m and Sonic Healthcare keeps writing cheques

LTR Pharma (ASX:LTP) lands 150,000-unit ROXUS deal that anchors the US story

Why Our Home Grown ASX Success Stories Are Doomed To Be Given Away on the Cheap, And What Could Be Done

Island Pharmaceuticals (ASX:ILA) starts GMP run that turns Galidesivir into a real biodefence asset

Opthea (ASX:OPT) returns from suspension with A$31.2m and a pivot to lung disease

Imagion Biosystems (ASX:IBX) gets FDA green light for HER2 trial, recruitment starts Q3

Memphasys (ASX:MEM) books 1,800 of 2,500 Felix cartridges in two quarters

Stocks in Spotlight

Investing in the Year of the Rat

2020, the Golden Year

Market trouble spots to avoid in 2020

Biotech Stocks

Stocks in Spotlight

Add Your Heading Text Here